

## Seikagaku at a Glance

**Specialization in glycoscience** for more than 60 years: a niche field difficult to enter by major pharmaceutical companies

### Industry's first

injectable hyaluronic acid products for osteoarthritis, holding top share in Japan for mainstay ARTZ®

**21.9%** R&D investment to net sales, ranking **5th** in

Japan's pharmaceutical industry (37 companies: FY2008)  
Our policy to invest 20% of net sales

Our mainstay product **ARTZ®** is approved in

**21 countries**

**17.4%** Operating Margin ranking **8th** in Japan's pharmaceutical industry (37 companies: FY2008)



**High-level extraction and purification technologies** ARTZ®: over two decades, more than 200 million injections without major side effects



**Global No.1**

in injectable hyaluronic acid products for osteoarthritis in terms of units sold

### Contents

Seikagaku at a Glance	1	Glycoscience	13	Financial Statements	16
Message from the President	2	Corporate Governance	14	Independent Auditors' Report	28
Performance by Segment	8	Board of Directors	15	Corporate Data	29
Main Products	9	Social Contribution through		Corporate History	BC
R&D Activities	10	Glycoscience Research Support	15		